826 related articles for article (PubMed ID: 24970922)
1. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease.
Gono T; Kaneko H; Kawaguchi Y; Hanaoka M; Kataoka S; Kuwana M; Takagi K; Ichida H; Katsumata Y; Ota Y; Kawasumi H; Yamanaka H
Rheumatology (Oxford); 2014 Dec; 53(12):2196-203. PubMed ID: 24970922
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
3. Comparison of cytokine profiles between anti-ARS antibody-positive interstitial lung diseases and those with anti-MDA-5 antibodies.
Asakawa K; Yoshizawa K; Aoki A; Kimura Y; Tanaka T; Ohashi K; Hayashi M; Kikuchi T; Sato S; Takada T
Clin Rheumatol; 2020 Jul; 39(7):2171-2178. PubMed ID: 32056068
[TBL] [Abstract][Full Text] [Related]
4. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
[TBL] [Abstract][Full Text] [Related]
5. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
Chen Z; Cao M; Plana MN; Liang J; Cai H; Kuwana M; Sun L
Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005
[TBL] [Abstract][Full Text] [Related]
6. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
[TBL] [Abstract][Full Text] [Related]
7. Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
Chen F; Li S; Wang T; Shi J; Wang G
Am J Med Sci; 2018 Jan; 355(1):48-53. PubMed ID: 29289262
[TBL] [Abstract][Full Text] [Related]
8. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
[TBL] [Abstract][Full Text] [Related]
9. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis.
Gono T; Kawaguchi Y; Satoh T; Kuwana M; Katsumata Y; Takagi K; Masuda I; Tochimoto A; Baba S; Okamoto Y; Ota Y; Yamanaka H
Rheumatology (Oxford); 2010 Sep; 49(9):1713-9. PubMed ID: 20498012
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics of dermatomyosits/polymyositis associated interstitial lung disease according to the autoantibody.
Kishaba T; McGill R; Nei Y; Ibuki S; Momose M; Nishiyama K; Nagano H; Yamashiro S
J Med Invest; 2018; 65(3.4):251-257. PubMed ID: 30282869
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study.
Ji SY; Zeng FQ; Guo Q; Tan GZ; Tang HF; Luo YJ; Tang ZQ; Han YF
Chin Med J (Engl); 2010 Mar; 123(5):517-22. PubMed ID: 20367973
[TBL] [Abstract][Full Text] [Related]
12. Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis.
Takada T; Aoki A; Asakawa K; Sakagami T; Moriyama H; Narita I; Sato S
Respir Med; 2015 Sep; 109(9):1174-80. PubMed ID: 26187000
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study.
Hozumi H; Enomoto N; Kono M; Fujisawa T; Inui N; Nakamura Y; Sumikawa H; Johkoh T; Nakashima R; Imura Y; Mimori T; Suda T
PLoS One; 2015; 10(3):e0120313. PubMed ID: 25789468
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
Enomoto Y; Suzuki Y; Hozumi H; Mori K; Kono M; Karayama M; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suzuki D; Ogawa N; Nakashima R; Mimori T; Iwashita T; Suda T
Arthritis Res Ther; 2017 Jan; 19(1):9. PubMed ID: 28103926
[TBL] [Abstract][Full Text] [Related]
15. IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis.
Shimizu T; Koga T; Furukawa K; Horai Y; Fujikawa K; Okada A; Okamoto M; Endo Y; Tsuji S; Takatani A; Umeda M; Fukui S; Sumiyoshi R; Kawashiri SY; Iwamoto N; Igawa T; Ichinose K; Tamai M; Sakamoto N; Nakamura H; Origuchi T; Mukae H; Kuwana M; Kawakami A
J Intern Med; 2021 Feb; 289(2):206-220. PubMed ID: 32691471
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease.
Kaieda S; Gono T; Masui K; Nishina N; Sato S; Kuwana M;
PLoS One; 2020; 15(6):e0234523. PubMed ID: 32525903
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis.
Hozumi H; Fujisawa T; Nakashima R; Yasui H; Suzuki Y; Kono M; Karayama M; Furuhashi K; Enomoto N; Inui N; Nakamura Y; Mimori T; Suda T
J Rheumatol; 2019 May; 46(5):509-517. PubMed ID: 30647164
[TBL] [Abstract][Full Text] [Related]
18. Elevated serum B-cell activating factor levels in patients with dermatomyositis: Association with interstitial lung disease.
Matsushita T; Kobayashi T; Kano M; Hamaguchi Y; Takehara K
J Dermatol; 2019 Dec; 46(12):1190-1196. PubMed ID: 31631384
[TBL] [Abstract][Full Text] [Related]
19. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease.
Li L; Wang H; Wang Q; Wu C; Liu C; Zhang Y; Cheng L; Zeng X; Zhang F; Li Y
J Neurol Sci; 2019 Feb; 397():123-128. PubMed ID: 30616054
[TBL] [Abstract][Full Text] [Related]
20. [The clinical significance of myositis-specific antibodies in polymyositis/dermatomyositis associated interstitial lung diseases].
Xie MM; Yan X; Li H; Ding JJ; Gui XH; Liu Y; Wang YS; Chen ZY; Cai HR
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Aug; 41(8):616-621. PubMed ID: 30138971
[No Abstract] [Full Text] [Related]
[Next] [New Search]
